Xcout Intel
Emulate, Inc.
Emulate, Inc. (Emulate) is a biotechnology company that commercialized Organs-on-Chips technology—a human cell-based technology that recreates organ-level function to model organs in healthy and diseased states. The technology has applications in pharmaceutical research, product development, testing how different medicines, chemicals, and foods affect human health. Emulate has also worked with Cedars-Sinai Medical Center on a precision medicine initiative that uses Organs-on-Chips technology in the clinical setting. This initiative is designed to provide clinicians with better data about how a
Subscribe to see Emulate, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Emulate, Inc. at a glance
Emulate, Inc. is a biotechnology company headquartered in United States, founded in 2014. Its most recent funding round raised $57.5M in August 2021. Xcout tracks 10 named people at Emulate, Inc., including Jim Corbett (CEO, Board Member).
Emulate, Inc. leadership
- Jim CorbettCEO, Board Member
- Lorna EwartChief Scientific officer
- Daniel LevnerCo-Founder, CTO
- Donald IngberScientific Founder, Board Member, Scientific Advisory Board Chairman
- Jack Parker-HolderCo-Founder
- Matthew McGillCo-Founder
4 more named people on record for Emulate, Inc., with roles, board committees and tenure — see the full roster →
Emulate, Inc. funding rounds
The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $57.5M | — | |
| Series E | $82M | 5 named | |
| SEC Form D filing | $19.3M | — | |
| SEC Form D filing | $28M | — | |
| SEC Form D filing | $36M | — | |
| SEC Form D filing | $745,750 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Emulate, Inc. news
Investors
Emulate, Inc. competitors
A few of Emulate, Inc.'s closest competitors — see the full list of competitors and alternatives →
Mimetas is a privately owned biotechnology company developing human organ-on-a-chip tissue models and products for drug development. The company also is involved in the testing of chemicals along with food and personalized medicine applications. The company is based in Oegstgeest and Enschede, The Netherlands, with subsidiairies in Gaithersburg (MD), United States, and Tokyo, Japan. Mimetas was founded in 2011 by Paul Vulto, Jos Joore, Bas Trietsch and Thomas Hankemeier. The company is co-led by Joore and Vulto as CEOs.
Organoid Therapeutics, Inc. is a biotechnology contract research organization (CRO) that provides human brain tissue models, neuronal phenotyping, drug screening, and machine learning-based analytical services. The company serves pharmaceutical, biotech, and academic researchers by conducting pre-clinical research and translational studies to evaluate drug efficacy, neurotoxicity, and neurological disease models.
iOrganBio is a biotechnology company founded in 2024 that develops AI-powered platforms for the precision engineering and manufacturing of human cells and organoids. The company's CellForge platform aims to create reproducible human cell models for research applications, including cardiac disease studies and biological simulation.
Hubrecht Organoid Technology (HUB) develops patented patient-derived organoid technology from healthy and diseased tissues to predict patient responses to treatments. The company functions as a contract research organization (CRO), offering drug discovery services, custom model and assay development, clinical trials in a dish, and licensing programs for pharmaceutical and research applications.
InSphero provides 3D in vitro cell culture models, microplates, organ-on-a-chip platforms, and related services for drug discovery and safety testing. The company serves pharmaceutical, biotechnology, and research organizations seeking non-animal testing alternatives to evaluate drug efficacy, liver safety, oncology, and other complex diseases.
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.
Get Emulate, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Emulate, Inc. in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 8 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access